Please login to the form below

Not currently logged in
Email:
Password:

UCB’s Mark Bodmer elected to BIA board

Will hold the position for a three-year fixed term

ucb mark bodmerUCB's Mark Bodmer has been elected to the board of UK trade body the BioIndustry Association (BIA).

Bodmer is VP, NewMedicines Therapeutics at UCB, having joined the company in 2012 as head of immunology.

As a board member of the BIA Bodmer will play a role in shaping the policy environment of the UK biotech industry. He will hold the role for three years, starting in January 2015.

Prior to joining UCB Bodmer served as senior VP of immunoinflammation, medicines discovery and development at GlaxoSmithKline.

His background also includes CEO appointments at three start-ups from 1996 to 2007: Hexagen, Lorantis and Biotica.

10th November 2014

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Numbers, navigation, and narratives: digital storytelling in medical communications
Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
Is this common data mistake killing your digital patient recruitment?
Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...